VANCOUVER, BC / ACCESSWIRE / September 30, 2016 / Marapharm Ventures Inc. (the "Company" or "Marapharm") Marapharm is pleased to announce that as part of the Corporation's long-term strategy to maximize shareholder value that the board has implemented a dividend policy as of today's date. The payment of future cash dividends is subject to the Board's determination to react to actual future market conditions in the interest of Marapharm. Linda Sampson, the company's CEO, states that, "this policy implementation is yet another sign that the company is optimistic about its prospects and is excited by this policy addition, as it defines how our shareholders will be rewarded in the future for their loyalty."
Linda Sampson, CEO, director, has exercised 400,000 share purchase options with a strike-price of $0.50 for total proceeds to the company of $200,000.
At the Company's Annual General Meeting (the "Meeting") held on September 16, 2016, Linda Sampson, Corey Klassen, and Yari Nieken were elected as directors of the Company and Saturna Group Chartered Accountants LLP were re-appointed as auditors of the Company for the ensuing year. The shareholders also approved the Company's 10% rolling stock option plan. There are 3,000,000 shares reserved for issuance under the stock option plan (the "Plan"). The Company has granted stock options to purchase 3,000,000 common shares of the Company at an exercise price of $0.50 per share exercisable in whole or in part for a period of 2 years from the date of grant.
Officers
Chief Executive Officer: Linda Sampson
Chief Financial Officer: Corey Klassen
Audit Committee
Linda Sampson
Corey Klassen
Yari Nieken
In addition, the Company is pleased to announce that it has engaged Pioneer Ventures Inc., Solar Properties Ltd., and Hilltop Business Center Inc. to provide various investor relations services to the Company. Pioneer Ventures Inc., Solar Properties Ltd., and Hilltop Business Center Inc. are Vancouver-based firms that provide advice and assistance on financings and access to capital markets. Pursuant to the consulting agreements, the Company has agreed to issue 1,000,000 common shares to each of Pioneer Ventures Inc., Solar Properties Ltd., and Hilltop Business Center Inc. during the term of the agreements. Pioneer Ventures Inc., Solar Properties Ltd., and Hilltop Business Center Inc. are beneficially owned and controlled by two shareholders of the Company who own an aggregate of 5.1% of the common shares, common share purchase warrants, and incentive stock options exercisable into 700,000 common shares of the Company at a price of $0.75 per share. The consulting agreements with Pioneer Ventures Inc., Solar Properties Ltd., and Hilltop Business Center Inc. and the issuances of shares under these agreements are subject to regulatory approval.
The Company is also pleased to announce that it has settled $207,752.46 in outstanding debt through an issuance of common shares. In order to preserve its cash to fund its Nevada and Washington projects, the Company has issued a total of 288,702 common shares at a price of $0.70 per share to settle the debt of $207,752.46 through two separate creditors.
The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.
For further information, please contact:
Linda Sampson
Chief Executive Officer & Director
Phone: 778-583-4476
ABOUT MARAPHARM VENTURES INC.
www.marapharm.com
Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (www.thecse.com), the OTC website (www.otcmarkets.com) and Sedar website (www.sedar.com) under the profile for Marapharm Ventures Inc.
FOR FURTHER INFORMATION:
www.marapharm.com or Linda Sampson, CEO, 778-583-4476
STOCK EXCHANGES:
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
FORWARD - LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", ‘may", "will", "project", "should", "believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.
SOURCE: Marapharm Ventures Inc.